AN2 Therapeutics reports Q3 2026 results, PV trial cleared in all planned jurisdictions
AN2 said its global Phase 2 epetraborole study in polycythemia vera has clearance to proceed everywhere planned and expects enrollment to start by year-end 2026.
AN2 Therapeutics reported third-quarter 2026 results on November 9, 2026, alongside updates across its boron chemistry pipeline.
AN2 anticipates commencing enrollment by the end of 2026, starting with an open-label sentinel cohort at a predicted subtherapeutic dose, followed by a safety committee review to guide dosing for Part 1, a 28-week open-label dose-escalation evaluation, with periodic Part 1 data expected throughout 2027.1
In M. abscessus lung disease, patient enrollment is ongoing in an 84-patient, multicenter, randomized, double-blind, placebo-controlled investigator-initiated trial led by Dr. Kevin Winthrop of Oregon Health and Science University across an estimated 10 to 15 U.S. sites, with topline results anticipated in late 2027, subject to enrollment progress.1
For Chagas disease, the company is advancing startup activities for a Phase 2 proof-of-concept study of AN2-502998 in adults with chronic T. cruzi infection.1
AN2 also named a new preclinical candidate, saying AN2-504661, an oral boron-based ENPP1 inhibitor, was selected as its development candidate for hypophosphatasia, with a Phase 1 study planned for the second half of 2027.1 Separately, the Gates Foundation extended funding to support AN2's tuberculosis research activities under its ongoing collaboration with GSK.1
The company said it held cash, cash equivalents and investments of $80.2 million as of September 30, 2026, which it projects will fund operations into 2029 under its current operating plan.1
Fact check notes
- Sentence removed
The company said startup activities are underway for a global Phase 2 study of oral epetraborole in adults with phlebotomy-dependent polycythemia vera, and it has received regulatory clearance to proceed in all planned jurisdictions, including U.S. FDA clearance of its IND, plus clearances in Australia and India.
copied source wording - Sentence removed
On financials, the condensed statements show net loss of $7,957 thousand for the third quarter of 2026 versus $9,353 thousand a year earlier.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.